In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Business Strategies Regulation

NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?

Executive Summary

NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?

You may also be interested in...



NicOx Blood Pressure Data Positive, But Is it Enough?

Shares in France's largest biotech, NicOx, received a small boost Dec. 17 after the company reported positive blood pressure data for Phase III-hopeful naproxcinod

NicOx Data Positive, But Is it Enough?

NicOx reported positive blood pressure data for Phase III osteoarthritis candidate naproxcinod, but pooled, post-hoc analyses may not be enough to differentiate the drug.

NicOx Gets Positive Results In Second Phase III Trial For Naproxcinod

In addition to meeting clinical endpoints, anti-inflammatory continues to show non-detrimental effect on blood pressure.

Table

View full table

Related Content

In Vivo
In Vivo
In Vivo
In Vivo

Topics

Related Companies

Tags:
BioPharmaceutical Business Strategies Regulation
Latest News

Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential

Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times

Dobbs Decision Could Have Knock-On Effects For Wider Reproductive Healthcare Landscape

Ways To Find And Nurture Young, Diverse Talent In Pharma

See All
UsernamePublicRestriction

Register

IV002898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By